Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Global change effects on plant communities are magnified by time and the number of global change factors imposed.

Komatsu KJ, Avolio ML, Lemoine NP, Isbell F, Grman E, Houseman GR, Koerner SE, Johnson DS, Wilcox KR, Alatalo JM, Anderson JP, Aerts R, Baer SG, Baldwin AH, Bates J, Beierkuhnlein C, Belote RT, Blair J, Bloor JMG, Bohlen PJ, Bork EW, Boughton EH, Bowman WD, Britton AJ, Cahill JF Jr, Chaneton E, Chiariello NR, Cheng J, Collins SL, Cornelissen JHC, Du G, Eskelinen A, Firn J, Foster B, Gough L, Gross K, Hallett LM, Han X, Harmens H, Hovenden MJ, Jagerbrand A, Jentsch A, Kern C, Klanderud K, Knapp AK, Kreyling J, Li W, Luo Y, McCulley RL, McLaren JR, Megonigal JP, Morgan JW, Onipchenko V, Pennings SC, Prevéy JS, Price JN, Reich PB, Robinson CH, Russell FL, Sala OE, Seabloom EW, Smith MD, Soudzilovskaia NA, Souza L, Suding K, Suttle KB, Svejcar T, Tilman D, Tognetti P, Turkington R, White S, Xu Z, Yahdjian L, Yu Q, Zhang P, Zhang Y.

Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17867-17873. doi: 10.1073/pnas.1819027116. Epub 2019 Aug 19.

PMID:
31427510
2.

Change in dominance determines herbivore effects on plant biodiversity.

Koerner SE, Smith MD, Burkepile DE, Hanan NP, Avolio ML, Collins SL, Knapp AK, Lemoine NP, Forrestel EJ, Eby S, Thompson DI, Aguado-Santacruz GA, Anderson JP, Anderson TM, Angassa A, Bagchi S, Bakker ES, Bastin G, Baur LE, Beard KH, Beever EA, Bohlen PJ, Boughton EH, Canestro D, Cesa A, Chaneton E, Cheng J, D'Antonio CM, Deleglise C, Dembélé F, Dorrough J, Eldridge DJ, Fernandez-Going B, Fernández-Lugo S, Fraser LH, Freedman B, García-Salgado G, Goheen JR, Guo L, Husheer S, Karembé M, Knops JMH, Kraaij T, Kulmatiski A, Kytöviita MM, Lezama F, Loucougaray G, Loydi A, Milchunas DG, Milton SJ, Morgan JW, Moxham C, Nehring KC, Olff H, Palmer TM, Rebollo S, Riginos C, Risch AC, Rueda M, Sankaran M, Sasaki T, Schoenecker KA, Schultz NL, Schütz M, Schwabe A, Siebert F, Smit C, Stahlheber KA, Storm C, Strong DJ, Su J, Tiruvaimozhi YV, Tyler C, Val J, Vandegehuchte ML, Veblen KE, Vermeire LT, Ward D, Wu J, Young TP, Yu Q, Zelikova TJ.

Nat Ecol Evol. 2018 Dec;2(12):1925-1932. doi: 10.1038/s41559-018-0696-y. Epub 2018 Oct 29.

3.

Assessing the success of hydrological restoration in two conservation easements within Central Florida ranchland.

Sonnier G, Bohlen PJ, Swain HM, Orzell SL, Bridges EL, Boughton EH.

PLoS One. 2018 Jul 3;13(7):e0199333. doi: 10.1371/journal.pone.0199333. eCollection 2018.

4.

Effect of environmental factors on level of trip disturbance: a simulation study.

Ming Liu, Bohlen P, Huang HH.

Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:5038-5041. doi: 10.1109/EMBC.2016.7591859.

PMID:
28269400
5.

Spatial and temporal disparity in signals and maskers affects signal detection in non-human primates.

Rocchi F, Dylla ME, Bohlen PA, Ramachandran R.

Hear Res. 2017 Feb;344:1-12. doi: 10.1016/j.heares.2016.10.013. Epub 2016 Oct 19.

6.

Prediction of Intrinsically Caused Tripping Events in Individuals With Stroke.

Zhang F, Bohlen P, Lewek MD, Huang H.

IEEE Trans Neural Syst Rehabil Eng. 2017 Aug;25(8):1202-1210. doi: 10.1109/TNSRE.2016.2614521. Epub 2016 Oct 11.

PMID:
27740490
7.

Detection of modulated tones in modulated noise by non-human primates.

Bohlen P, Dylla M, Timms C, Ramachandran R.

J Assoc Res Otolaryngol. 2014 Oct;15(5):801-21. doi: 10.1007/s10162-014-0467-7. Epub 2014 Jun 5.

8.

Controlling runoff from subtropical pastures has differential effects on nitrogen and phosphorus loads.

Bohlen PJ, Villapando OR.

J Environ Qual. 2013 Jul;42(4):1281. doi: 10.2134/jeq2010.0127er. No abstract available.

PMID:
24216380
9.

Earthworm effects on the incorporation of litter C and N into soil organic matter in a sugar maple forest.

Fahey TJ, Yavitt JB, Sherman RE, Maerz JC, Groffman PM, Fisk MC, Bohlen PJ.

Ecol Appl. 2013 Jul;23(5):1185-201.

PMID:
23967585
10.

Controlling runoff from subtropical pastures has differential effects on nitrogen and phosphorus loads.

Bohlen PJ, Villapando OR.

J Environ Qual. 2011 May-Jun;40(3):989-98. doi: 10.2134/jeq2010.0127.

PMID:
21546685
11.

Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.

Duncton MA, Piatnitski Chekler EL, Katoch-Rouse R, Sherman D, Wong WC, Smith LM 2nd, Kawakami JK, Kiselyov AS, Milligan DL, Balagtas C, Hadari YR, Wang Y, Patel SN, Rolster RL, Tonra JR, Surguladze D, Mitelman S, Kussie P, Bohlen P, Doody JF.

Bioorg Med Chem. 2009 Jan 15;17(2):731-40. doi: 10.1016/j.bmc.2008.11.049. Epub 2008 Nov 24.

PMID:
19101155
12.

Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys.

Sun HD, Malabunga M, Tonra JR, DiRenzo R, Carrick FE, Zheng H, Berthoud HR, McGuinness OP, Shen J, Bohlen P, Leibel RL, Kussie P.

Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E964-76. Epub 2006 Nov 28.

13.

Patterns of litter disappearance in a northern hardwood forest invaded by exotic earthworms.

Suárez ER, Fahey TJ, Yavitt JB, Groffman PM, Bohlen PJ.

Ecol Appl. 2006 Feb;16(1):154-65.

PMID:
16705969
14.

The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.

Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, Hicklin DJ.

Int J Cancer. 2006 Oct 1;119(7):1519-29.

15.

Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells.

Karajannis MA, Vincent L, Direnzo R, Shmelkov SV, Zhang F, Feldman EJ, Bohlen P, Zhu Z, Sun H, Kussie P, Rafii S.

Leukemia. 2006 Jun;20(6):979-86.

PMID:
16598308
16.

Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants.

Miller DW, Vosseler S, Mirancea N, Hicklin DJ, Bohlen P, Völcker HE, Holz FG, Fusenig NE.

Am J Pathol. 2005 Nov;167(5):1389-403.

17.

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.

Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S.

J Clin Invest. 2005 Nov;115(11):2992-3006. Epub 2005 Oct 13.

18.
19.

Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.

Vincent L, Jin DK, Karajannis MA, Shido K, Hooper AT, Rashbaum WK, Pytowski B, Wu Y, Hicklin DJ, Zhu Z, Bohlen P, Niesvizky R, Rafii S.

Cancer Res. 2005 Apr 15;65(8):3185-92.

20.

Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.

Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, Rolser R, Malikzay A, Persaud A, Corcoran E, Deevi DS, Balderes P, Bassi R, Jimenez X, Joynes CJ, Mangalampalli VR, Steiner P, Tonra JR, Wu Y, Pereira DS, Zhu Z, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Kussie P.

Mol Cancer Ther. 2005 Mar;4(3):369-79.

21.

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Zhu Z.

J Biol Chem. 2005 May 20;280(20):19665-72. Epub 2005 Mar 9.

23.

Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature.

May C, Doody JF, Abdullah R, Balderes P, Xu X, Chen CP, Zhu Z, Shapiro L, Kussie P, Hicklin DJ, Liao F, Bohlen P.

Blood. 2005 Jun 1;105(11):4337-44. Epub 2005 Feb 8.

PMID:
15701713
24.

Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed.

Ludwig DL, Witte L, Hicklin DJ, Prewett M, Bassi R, Burtrum D, Pereira DS, Jimenez X, Fox F, Saxena B, Zhou Q, Ma Y, Kang X, Patel D, Barry M, Kussie P, Zhu Z, Russell DA, Petersen WL, Jury TP, Gaitan-Gaitan F, Moran DL, Delannay X, Storrs BS, Tou J, Zupec ME, Gustafson KS, McIntyre J, Tarnowski SJ, Bohlen P.

Hum Antibodies. 2004;13(3):81-90. Erratum in: Hum Antibodies. 2009;18(4):157. Dosage error in article text.

PMID:
15598988
25.

The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent.

Pauli SA, Tang H, Wang J, Bohlen P, Posser R, Hartman T, Sauer MV, Kitajewski J, Zimmermann RC.

Endocrinology. 2005 Mar;146(3):1301-11. Epub 2004 Dec 9.

PMID:
15591152
26.

Inhibition of the vascular endothelial cell (VE)-specific adhesion molecule VE-cadherin blocks gonadotropin-dependent folliculogenesis and corpus luteum formation and angiogenesis.

Nakhuda GS, Zimmermann RC, Bohlen P, Liao F, Sauer MV, Kitajewski J.

Endocrinology. 2005 Mar;146(3):1053-9. Epub 2004 Dec 9.

PMID:
15591148
27.

Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2.

Zhang H, Li Y, Li H, Bassi R, Jimenez X, Witte L, Bohlen P, Hicklin D, Zhu Z.

Leuk Lymphoma. 2004 Sep;45(9):1887-97.

PMID:
15223651
28.

Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.

Kiessling F, Farhan N, Lichy MP, Vosseler S, Heilmann M, Krix M, Bohlen P, Miller DW, Mueller MM, Semmler W, Fusenig NE, Delorme S.

Neoplasia. 2004 May-Jun;6(3):213-23.

29.

VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins.

Hong YK, Lange-Asschenfeldt B, Velasco P, Hirakawa S, Kunstfeld R, Brown LF, Bohlen P, Senger DR, Detmar M.

FASEB J. 2004 Jul;18(10):1111-3. Epub 2004 May 7.

PMID:
15132990
30.

Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.

Li Y, Li H, Wang MN, Lu D, Bassi R, Wu Y, Zhang H, Balderes P, Ludwig DL, Pytowski B, Kussie P, Piloto O, Small D, Bohlen P, Witte L, Zhu Z, Hicklin DJ.

Blood. 2004 Aug 15;104(4):1137-44. Epub 2004 Apr 22.

PMID:
15105287
31.

Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia.

Kunstfeld R, Hirakawa S, Hong YK, Schacht V, Lange-Asschenfeldt B, Velasco P, Lin C, Fiebiger E, Wei X, Wu Y, Hicklin D, Bohlen P, Detmar M.

Blood. 2004 Aug 15;104(4):1048-57. Epub 2004 Apr 20.

PMID:
15100155
32.

Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis.

Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, Jin DK, Dias S, Zhang F, Hartman TE, Hackett NR, Crystal RG, Witte L, Hicklin DJ, Bohlen P, Eaton D, Lyden D, de Sauvage F, Rafii S.

Nat Med. 2004 Jan;10(1):64-71. Epub 2003 Dec 21.

PMID:
14702636
33.

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL.

Cancer Res. 2003 Dec 15;63(24):8912-21.

34.

Vaccination against angiogenesis-associated antigens: a novel cancer immunotherapy strategy.

Li Y, Bohlen P, Hicklin DJ.

Curr Mol Med. 2003 Dec;3(8):773-9. Review.

PMID:
14682497
35.

Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography.

Krix M, Kiessling F, Vosseler S, Farhan N, Mueller MM, Bohlen P, Fusenig NE, Delorme S.

Cancer Res. 2003 Dec 1;63(23):8264-70.

36.

Monoclonal antibody therapeutics and apoptosis.

Ludwig DL, Pereira DS, Zhu Z, Hicklin DJ, Bohlen P.

Oncogene. 2003 Dec 8;22(56):9097-106. Review.

PMID:
14663488
37.

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L, Zhu Z.

J Biol Chem. 2004 Jan 23;279(4):2856-65. Epub 2003 Oct 23.

38.

Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis.

De Bandt M, Ben Mahdi MH, Ollivier V, Grossin M, Dupuis M, Gaudry M, Bohlen P, Lipson KE, Rice A, Wu Y, Gougerot-Pocidalo MA, Pasquier C.

J Immunol. 2003 Nov 1;171(9):4853-9.

39.

Di-diabody: a novel tetravalent bispecific antibody molecule by design.

Lu D, Jimenez X, Zhang H, Atkins A, Brennan L, Balderes P, Bohlen P, Witte L, Zhu Z.

J Immunol Methods. 2003 Aug;279(1-2):219-32.

PMID:
12969563
40.

Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development.

Zimmermann RC, Hartman T, Kavic S, Pauli SA, Bohlen P, Sauer MV, Kitajewski J.

J Clin Invest. 2003 Sep;112(5):659-69.

41.

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.

Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z.

J Biol Chem. 2003 Oct 31;278(44):43496-507. Epub 2003 Aug 12.

42.

Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.

Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D, Liu M, Tejada R, Friedrich M, Bohlen P, Witte L, Rafii S.

Leukemia. 2003 Mar;17(3):604-11.

PMID:
12646950
43.

Cloning, expression, and purification of mouse heparanase.

Miao HQ, Navarro E, Patel S, Sargent D, Koo H, Wan H, Plata A, Zhou Q, Ludwig D, Bohlen P, Kussie P.

Protein Expr Purif. 2002 Dec;26(3):425-31.

PMID:
12460766
44.

Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.

Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carpenter M, Hicklin DJ, Bohlen P, Raisch KP.

Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1180-93.

PMID:
12419447
45.

Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.

Zhu Z, Bohlen P, Witte L.

Curr Cancer Drug Targets. 2002 Jun;2(2):135-56. Review.

PMID:
12188915
46.

Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments.

Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z.

J Immunol Methods. 2002 Sep 15;267(2):213-26.

PMID:
12165442
47.

A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability.

Corada M, Zanetta L, Orsenigo F, Breviario F, Lampugnani MG, Bernasconi S, Liao F, Hicklin DJ, Bohlen P, Dejana E.

Blood. 2002 Aug 1;100(3):905-11.

PMID:
12130501
48.

Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment.

Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, Hicklin DJ, Zhu Z, Bohlen P, Witte L, Hendrikx J, Hackett NR, Crystal RG, Moore MA, Werb Z, Lyden D, Rafii S.

Nat Med. 2002 Aug;8(8):841-9. Epub 2002 Jul 1.

49.

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.

Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, Carmeliet P.

Nat Med. 2002 Aug;8(8):831-40. Epub 2002 Jul 1.

PMID:
12091877

Supplemental Content

Loading ...
Support Center